File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Utilization of international normalized ratio‐derived formula to predict plasma rivaroxaban level—Validation study and real‐world experience

TitleUtilization of international normalized ratio‐derived formula to predict plasma rivaroxaban level—Validation study and real‐world experience
Authors
Issue Date17-Jul-2024
PublisherWiley
Citation
International Journal of Laboratory Hematology, 2024 How to Cite?
Abstract

Introduction
Specific assays of plasma rivaroxaban level are not always readily available with short turnaround time, which hamper the management of urgent clinical situations. In this study, we aimed to build a predictive formula of plasma rivaroxaban levels from international normalized ratio (INR) value and validated in real world clinical situations.

Methods
Ninety-four patients who were taking rivaroxaban participated in the study. Patients were randomized into testing cohort and validation cohorts. The prediction formula was built from the testing cohort and then validated in validation cohort. The predictive performance was further validated on real-world clinical requests.

Results
The root mean square error (RMSE) of the predictive formula for the testing and validation cohorts were 61.81 and 69.32 ng/mL, respectively. The sensitivity and specificity for the formula to predict the threshold plasma rivaroxaban level of 75 ng/mL were 95% (95% CI: 85.4%–100%) and 87.5% (95% CI: 71.3%–100%), respectively, in real-world clinical situations.

Conclusion
Plasma rivaroxaban level of threshold level of 75 ng/mL can be calculated from prediction formula by INR value with satisfactory accuracy and it can be used to guide the decision for reversal.


Persistent Identifierhttp://hdl.handle.net/10722/347825
ISSN
2023 Impact Factor: 2.2
2023 SCImago Journal Rankings: 0.555

 

DC FieldValueLanguage
dc.contributor.authorSin, Chun‐Fung-
dc.contributor.authorWong, Ka‐ping-
dc.contributor.authorSiu, Chun Wah-
dc.contributor.authorWong, Tsz‐fu-
dc.contributor.authorWong, Hoi‐man-
dc.date.accessioned2024-10-01T00:30:32Z-
dc.date.available2024-10-01T00:30:32Z-
dc.date.issued2024-07-17-
dc.identifier.citationInternational Journal of Laboratory Hematology, 2024-
dc.identifier.issn1751-5521-
dc.identifier.urihttp://hdl.handle.net/10722/347825-
dc.description.abstract<p>Introduction<br>Specific assays of plasma rivaroxaban level are not always readily available with short turnaround time, which hamper the management of urgent clinical situations. In this study, we aimed to build a predictive formula of plasma rivaroxaban levels from international normalized ratio (INR) value and validated in real world clinical situations.</p><p>Methods<br>Ninety-four patients who were taking rivaroxaban participated in the study. Patients were randomized into testing cohort and validation cohorts. The prediction formula was built from the testing cohort and then validated in validation cohort. The predictive performance was further validated on real-world clinical requests.</p><p>Results<br>The root mean square error (RMSE) of the predictive formula for the testing and validation cohorts were 61.81 and 69.32 ng/mL, respectively. The sensitivity and specificity for the formula to predict the threshold plasma rivaroxaban level of 75 ng/mL were 95% (95% CI: 85.4%–100%) and 87.5% (95% CI: 71.3%–100%), respectively, in real-world clinical situations.</p><p>Conclusion<br>Plasma rivaroxaban level of threshold level of 75 ng/mL can be calculated from prediction formula by INR value with satisfactory accuracy and it can be used to guide the decision for reversal.</p>-
dc.languageeng-
dc.publisherWiley-
dc.relation.ispartofInternational Journal of Laboratory Hematology-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleUtilization of international normalized ratio‐derived formula to predict plasma rivaroxaban level—Validation study and real‐world experience-
dc.typeArticle-
dc.identifier.doi10.1111/ijlh.14347-
dc.identifier.eissn1751-553X-
dc.identifier.issnl1751-5521-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats